Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165348 | 0.86 | LMNA (0.43) | ACP3HTR2ARETCHRNA7PRCP | |
| SCHEMBL4043081 | 0.83 | SLC18A3 (0.41) | ACP3HTR2ARETCHRNA7HTT | |
| SCHEMBL4157911 | 0.82 | GID4 (0.48) | HTR2A | |
| SCHEMBL4039398 | 0.80 | GID4 (0.49) | HTR2A | |
| SCHEMBL12259452 | 0.78 | CYP1A2 (0.46) | EPHX1TSHRGBA1 | |
| SCHEMBL10754709 | 0.76 | HTR2A (0.50) | ACP3HTR2ARETPRCP | |
| SCHEMBL4162181 | 0.75 | ACP3 (0.39) | ACP3HTR2ARETPRCP | |
| SCHEMBL4170076 | 0.75 | CETP (0.46) | — | |
| SCHEMBL5102163 | 0.74 | PRCP (0.63) | PRCPTSHRNPSR1GAA | |
| SCHEMBL10739890 | 0.73 | ACP3 (0.47) | ACP3HTR2ARETMTNR1BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | ACP3 990/4885HTR2A 574/4885RET 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.